



Company name: GNI Ltd.
Representative: Dr. Christopher Savoie, Chief Executive Officer
Stock listing: TSE Mothers (Code: 2160)
Media inquiries: Deborah Hayden
(Phone: + 81-3-5404-0640 e-mail: dhayden@gene-networks.com)

GNI Successfully Completes IPO

TOKYO, September 3, 2007 - GNI Ltd., a drug discovery/pharmaceutical company in Asia, announced it has successfully completed an offering of new shares in connection with the company's listing on the Mothers market of the Tokyo Stock Exchange on August 31. A total of 10 million shares were issued at 90 yen per share.

Founded in 2001, GNI is a multinational pharmaceutical company dedicated to the discovery, development, and commercialization of new drugs for the treatment of diseases prevalent in Asia. GNI applies gene network analysis and other biotech tools to develop drugs to alleviate suffering from pulmonary disease, liver cirrhosis, cancer, inflammation, and other medical conditions.

GNI's chairman, chief executive officer and founder, Dr. Christopher Savoie, said:

"This is an important milestone in GNI's history. We intend to use the capital raised to advance our products towards commercialization and to be partners with companies worldwide in the discovery and development of drugs arising out of our gene networks analysis."

GNI's shares will trade under the ticker symbol 2160. Please refer to the TSE homepage at <http://www.tse.or.jp> for details of the listing of GNI shares on the Mothers market.

This communication does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Notes to editors

About GNI

Founded in 2001, GNI is a drug discovery/pharmaceutical company with operations in Japan, China and the U.S. In June 2005, Shanghai Genomics, which operates an integrated drug discovery platform combining genetic discovery and drug development, became an affiliate of GNI. For further information, please visit www.gene-networks.com.